Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: JMarcus who wrote (9440)	11/7/2003 5:22:03 PM
From: Biomaven	Respond to of 52153

We expect to have multiple peer-reviewed scientific publications of data from our clinical trials with Multikine published during the next 12 months, including one before the end of this year. Well that might be the time then for him to start saying this stuff... (But I suspect the trials are very small and so the data may still not prove much one way or the other). OTOH, there is some chance the stuff might have some effect. IL-2 works (to a limited extent) in some cancers, so a cocktail of IL-2 and other cytokine-like stuff might conceivably work better. Here's a recent abstract on Multikine: Arch Otolaryngol Head Neck Surg. 2003 Aug;129(8):874-81. Related Articles, Links Report of a clinical trial in 12 patients with head and neck cancer treated intratumorally and peritumorally with multikine. Feinmesser R, Hardy B, Sadov R, Shwartz A, Chretien P, Feinmesser M. Department of Otolaryngology and Head and Neck Surgery, Rabin Medical Center, Petah Tiqwa, Israel. feinmesserr@clalit.org.il BACKGROUND: There is cumulative evidence suggesting that cells of the immune system recognize and may participate in eradicating neoplastic cells. As a result, immune modulation, first with interleukin 2 and later with other cytokines, has been tried in the clinical setting as part of antitumor therapy. OBJECTIVE: To examine the effectiveness and toxicity of a combination of natural interleukins in patients with squamous cell head and neck cancer. METHODS: Twelve previously untreated patients with various head and neck cancers were treated by peritumoral injection of a combination of cytokines (Multikine), in addition to zinc sulfate, indomethacin, and a single dose of cyclophosphamide, which were administered systemically. Response was evaluated clinically and histopathologically. T-lymphocyte determinants were studied by fluorescence-activated cell sorter analysis (against controls). RESULTS: Two patients showed complete regression and another 2 showed partial regression. There were no serious adverse effects of treatment. Pathological study results showed tumor fragmentation and the appearance of multinucleated macrophages. Fluorescence-activated cell sorter analysis showed lymphocyte activation, reflected by an unusually high number of cytotoxic T-lymphocyte activation 4 cells and natural killer cells. CONCLUSION: Multikine warrants further investigation for inclusion in the pharmacotherapeutic armamentarium of head and neck cancer.